ANVISA Guidelines on Participant Involvement in Clinical Trials [Regulatives / Guidelines]

posted by Rajul9  – India, 2024-11-24 19:19 (180 d 01:45 ago) – Posting: # 24296
Views: 1,886

Hi all,

I’m looking for clarification on ANVISA’s regulations regarding participant eligibility for clinical trials, particularly:

Are there restrictions, such as a required gap (e.g., 180 days) after participation in another trial or blood donation?
Where can I find this information in ANVISA’s guidelines?
What’s the best way to contact ANVISA for further clarification?
Any specific references or insights would be greatly appreciated!

Thanks!

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,683 registered users;
42 visitors (0 registered, 42 guests [including 21 identified bots]).
Forum time: 22:04 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5